Trial Profile
A Phase II, Randomized, Open Label, 2-Way Crossover, Safety Study of Subcutaneously Injected Prandial INSULIN-PH20 NP Compared to Insulin Analog Injection in Patients With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin aspart; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Halozyme Therapeutics
- 05 Oct 2012 Multiple endpoints added and patient numbers updated to 117
- 05 Oct 2012 The primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met for non-inferiority
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.